ASH 2023 | Investigating mechanisms of resistance to immunotherapy in AML: the role of TP53 aberrations
Lis Winter, MSc, Ludwig-Maximilians-University of Munich, Munich, Germany, shares findings from a study investigating whether aberrations in TP53 contribute to intrinsic and extrinsic mechanisms of resistance to T-cell based immunotherapies in acute myeloid leukemia (AML). In this study, the AML cell line MV4-11 was used, and results demonstrated that AML cells carrying TP53 aberrations were less susceptible to bispecific antibody (BsAb)-mediated cytotoxicity. There was also a decrease in T-cell proliferation and cytokine secretion observed, indicating that TP53 aberrations contribute to resistance, although further research is required. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
